<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994899</url>
  </required_header>
  <id_info>
    <org_study_id>Aiberry Depression</org_study_id>
    <nct_id>NCT04994899</nct_id>
  </id_info>
  <brief_title>A Controlled Clinical Trial to Train the Aiberry AI Depression Detection Platform</brief_title>
  <official_title>A Controlled Clinical Trial to Train the Aiberry AI Depression Detection Platform on a Diverse Set of Population in a Live Setting and Further Enhance the Detection Accuracy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aiberry, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aiberry, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This controlled, multicenter trial will train and validate the Aiberry platform's ability to&#xD;
      detect depression in a diverse patient population. Up to 10 sites in the United States will&#xD;
      participate in this protocol. Adults and children may participate (ages 13-79). A total of&#xD;
      1,000 eligible subjects will complete depression screenings and an Aiberry video recorded&#xD;
      interview during 1 clinic visit. Analysis will be stratified by depression diagnosis status,&#xD;
      race/ethnicity, and age. Subjects will participate in a baseline questionnaire to collect&#xD;
      demographic information and health history.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Train the Aiberry platform on a diverse patient population</measure>
    <time_frame>2021-2022</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predict depression at higher degree of accuracy than standard paper-based screening instruments</measure>
    <time_frame>2021-2022</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test, train and implement the Aiberry platform in a live environment</measure>
    <time_frame>2021-2022</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Interview &amp; Depression Screening</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aiberry Depression Detection AI Platform</intervention_name>
    <description>Aiberry is a next-generation artificial intelligence (AI) company that leverages deep tech to screen for mental health and brain-related disorders.</description>
    <arm_group_label>Interview &amp; Depression Screening</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with or without prior mental health diagnosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 13 to 79 years old&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participant in the study&#xD;
&#xD;
          -  Individuals unable to verbally respond to standardized questions&#xD;
&#xD;
          -  Individuals unable to participate in a virtual visit as they do not have the right&#xD;
             hardware (phone/laptop) or no internet connectivity&#xD;
&#xD;
          -  Individuals unable to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hart Clinical Consultants</last_name>
    <phone>803-315-0077</phone>
    <email>patric.mercer@hartclinicalconsultants.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

